Skip to content

Metabolic Consequences of Cross-sex Hormonal Treatment

Metabolic Consequences of Cross-sex Hormonal Treatment in Transgender Persons

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04508231
Acronym
DysGeMet
Enrollment
98
Registered
2020-08-11
Start date
2020-07-24
Completion date
2021-12-01
Last updated
2020-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gender Dysphoria

Brief summary

Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls

Interventions

Gender-affirming hormone therapy according to the recommendations of the Endocrine Society

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

(retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits) * age \>= 16 years (Tanner stage IV) and \<= 50 years at the initiation of gender-affirming hormone therapy; * BMI \< 28 kg/m2 at the initiation of cross-sex hormonal treatment.

Exclusion criteria

* hormonal contraception * previous gender-affirming hormonal treatment * previous gender-affirming surgery * recognized syndrome or chromosomal defect, known metabolic or inflammatory disease, skeletal dysplasia, or chronic corticosteroid treatment.

Design outcomes

Primary

MeasureTime frameDescription
Retrospective analysis of existing data collected as a part of the regular follow-upRetrospective analysis of data between 2004 and 2019Retrospective analysis of existing data :Anthropometric parameters, including systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight and height at fasting state, were measured in all subjects at the occasion of the routine follow-up visits. Body mass index (BMI) was calculated as body weight in kilograms divided by the height in meter squared (kg/m2). Body composition parameters, including lean mass (LM), total body fat (BF), android and gynoid fat, and bone mineral content, were determined using dual-energy X-Ray absorbtiometry (DXA) (GE-Healthcare Lunar iDXA system), biochemical and routine hormonal analysis

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026